T
Taj For DoctorsTaj Doctor
home

About Us

Taj Brands

Diseases Health Tips  HIV/AIDS News Contact Us

 

  All News
  Allergy
  Asthma
  Cardiology
  Clinical Research
  Critical Care
  Dentistry
  Dermatology
  Endocrinology
  Gastroenterology
  General
  Genetics / Biotech
  Men's Health
  Infectious Diseases
  Fitness/Lifestyle
  Nephrology
  Neurology
  Oncology/Haematology
  Ophthalmology
  Orthopaedics
  Otolaryngology
  Paediatrics
  Psychiatry
  Reproductive Health
  Respiratory Medicine
  Surgery
  Sex
  Urology
  Women's Health
Taj Brands


Therapeutic Index

Dectrovir-N TM

Composition:

Lamivudine           ............................................................150 mg

Zidovudine USP   ............................................................300 mg

Nevirapine             ............................................................200 mg

 

Indications:

Dectrovir-N is indicated for the treatment of HIV infection, once patients have been stabilized on the maintenance regimen of nevirapine 200 mg bd, and have demonstrated adequate tolerability to nevirapine.

 

Description:

Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. Nevirapine is, in general, only prescribed after the immune system has declined and infections have become evident. It is always taken with at least one other HIV medication such as Retrovir or Videx. The virus can develop resistance to nevirapine if the drug is taken alone, although even if used properly, nevirapine is effective for only a limited time.

Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates.

 

Side Effects

In controlled clinical trials, the most common Nevirapine side effect was rash, which in 7.6% of subjects was considered severe. Increases in the liver enzymes occurred in 5-10% of subjects compared with 2-5% in controls.

 

CONTRAINDICATIONS:

Nevirapine is contraindicated in patients with clinically significant hypersensitivity to any of the components contained in the tablet or the oral suspension.

 

Drug Interaction

Nevirapine is principally metabolized by the liver via the cytochrome P450 isoenzymes, 3A4 and 2B6. Nevirapine is known to be an inducer of these enzymes. As a result, drugs that are metabolized by these enzyme systems may have lower than expected plasma levels when coadministered with nevirapine.

 

Dosage: Adults: 1 tablet twice daily or as per the physicianís advice.

Presentations:       30 tablets             

                                      MRP            Retailer           Stockist

                                    675.00           540.00              486.00

 
 

         Copyright © 2004- 2006 TAJ Pharmaceuticals Limited. All Rights Reserved.

Site Requirements : Internet Explorer 5.0+ or Netscape 5.0+, Flash Player 5.0 & Real Player 8 Basic
To get in touch with us, call on 91-22-2637 4592, 91--22-2637 4593 or fax us at 91-22-2634 1274 

Terms and Conditions | Disclaimer | Privacy Policy | Sitemap | Feedback | FAQ